What does Unitree’s Shanghai IPO mean if you own one of its robots?
Unitree's robot dogs and humanoids now carry a stock ticker in Shanghai. A share listing has rules and a regulator. What does it disclose about the machine you own?
On this page3 sections
Unitree makes robots a regular person can already own. Its Go2 robot dog has sold since 2023, and its G1 humanoid went on sale in 2024 at about $16,000. On August 19, 2026, the company that builds them became something else too, a public company on the Shanghai Stock Exchange’s STAR Market, trading under the ticker 688836.
Unitree priced the sale at 150.8 yuan a share, about $22, which valued the firm near 61 billion yuan, or roughly $9 billion. That made it the first large humanoid maker to list on mainland China, with DeepSeek among its strategic investors.
Before deciding what that changes, it helps to know what the listing is. A share sale is a financial instrument with its own rules, its own regulator and a stack of paperwork, and nearly all of that paperwork is written for investors rather than owners.
So the useful question for someone who already paid for the robot is narrow. Does any of it tell you something about the machine you could not learn before?
What a Shanghai listing actually is
Reaching the STAR Market took Unitree more than a year, inside a process run by two bodies. The Shanghai Stock Exchange took in the application in March 2026 and its listing committee cleared it on June 1. In early July the China Securities Regulatory Commission approved the registration, and the sale followed in August.
What that approval tests is narrow, and easy to read as more than it is. The exchange and the regulator work through one question above all: has the company told investors enough, and clearly enough, to judge it for themselves.
Term
Registration-based listingOn the STAR Market, China’s securities regulator clears a share sale by confirming the company has disclosed its finances and risks in full and meets the listing standards. It weighs the completeness of the disclosure, not whether the product is any good.The document at the center of it is the prospectus, a disclosure filing written so investors can price the risk they are taking. It runs to hundreds of pages about the business, and says almost nothing a buyer would recognize as being about the robot itself.
What the prospectus put on the record
The filing made public numbers Unitree had never had to publish. In 2025 revenue more than quadrupled to about 1.7 billion yuan, and for the first time humanoids passed robot dogs as the biggest earner, at 868 million yuan, close to 52% of core sales.
Most of that humanoid money does not come from homes. Through the first three quarters of 2025, about 73.6% of humanoid revenue came from research and education buyers and roughly 9% from industry. The machine in a living room is, commercially, a side case.
The margins are moving as well. Humanoid gross margin has slid to about 63% from nearly 88% in 2023 as prices fall and rivals pile in, and in early 2026 adjusted net profit dropped by roughly half even as sales grew. The company warns, in its own terms, that performance could see significant fluctuations or even a marked decline.
The filing is frank about gaps, too. Unitree holds relatively few core invention patents, which it says is not enough to fully protect its technology. Its own general-purpose AI models, the software meant to make a humanoid broadly useful, are not yet running at scale on its products, and nearly half the money raised is set aside to close that gap.
Then there is the part a US owner will notice. Overseas sales have run above 35% of revenue, with the United States about 13% of the total, and the prospectus names US tariffs, export controls and restricted lists as a live threat to supply and growth.
In May 2025 a US House committee had already asked for Unitree to be labeled a Chinese military company and added to the Entity List.
What a share listing answers for a robot owner, and what it leaves out
| What an owner wants to know | What the listing answers |
|---|---|
| Is the robot in my home safe to run? | Nothing. No product-safety regulator reviewed the machines for the sale. |
| Will it keep getting software updates? | Only through the company finances the filing now makes public. |
| Who actually buys these robots? | Mostly research and education, where the humanoid sales come from. |
| Could US rules choke off parts or support? | Named as a risk. Tariffs and export controls sit in the filing. |
None of those lines is a finding about whether the robot in your home is safe to run.
What it does not touch
No product-safety regulator sat in the listing process. The securities regulator and the exchange examine financial disclosure, and neither tested a Go2 or a G1 for the things an owner worries about, from a walking humanoid’s pinch points to heat at a charging dock. A prospectus discloses a company’s business risk to its would-be shareholders, and certifies nothing about the robot already in someone’s home.
The listing does change one thing, quieter than a $9 billion valuation. A public company has to keep disclosing. From here, the clearest early signal about whether Unitree can keep funding the software a humanoid leans on may arrive as a line in a quarterly filing, read by analysts in Shanghai, long before it reaches an owner as a notice in an app.
